Nanotoxicity of Drug Delivery Systems for Cancer Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 258
Special Issue Editor
Special Issue Information
Dear Colleagues,
Benefiting from the rapid advancement of nanotechnology, nanoparticles have emerged as a pivotal strategy for improving the drug delivery of anticancer drugs. The utilization of nanoscale drug delivery systems holds the potential to enhance drug accumulation, penetration, and targeted uptake within tumor tissues while also enabling controlled drug release. With the widening array of nanomaterials integrated into drug delivery systems, concerns regarding nanotoxicity have gained prominence. The interplay between nanomaterials, distinguished by their nanoscale dimensions, and biological tissue, cells, and microenvironments can expose adverse effects. However, despite the widespread use of nanomedicines, our understanding of the toxicity they may induce remains constrained.
This Special Issue aims to publish high-quality research papers and reviews focusing on recent advances, outcomes, and correlations between toxicity and nanomaterial-based drug delivery systems for cancer therapy. This Special Issue invites manuscripts ranging from understanding cellular toxicity, whole animal toxicity, neurotoxicity, immunotoxicity, genotoxicity, and population-scale effects.
Dr. Ilya Yakavets
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nano-based drug delivery systems
- nanocarriers
- cancer therapy
- organic/inorganic nanoparticles
- lipid-based nanoparticles, polymeric NPs/micelles
- cell toxicity
- immunotoxicity
- genotoxicity
- animal toxicity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
